Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML

Background Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of exi...

Full description

Bibliographic Details
Main Authors: R Eric Davis, Marina Konopleva, Natalia Baran, Gheath Al-Atrash, Naval Daver, Shelley Herbrich, Tianyu Cai, Connie Weng, Marisa J L Aitken, Sean M Post, Jared Henderson, Chunhua Shi, Guillame Richard-Carpentier, Guy Sauvageau, Keith Baggerly, Dongxing Zha
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002968.full